Diabetic Macular Edema - Pipeline Review, H2 2017

of 13 /13
www.MarketResearchReports.com Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.

Embed Size (px)

Transcript of Diabetic Macular Edema - Pipeline Review, H2 2017

  • www.MarketResearchReports.com

    Category : Pharma & Healthcare

    All logos and Images mentioned on this slide belong to their respective owners.

  • www.MarketResearchReports.com

    Introduction to Report

    Launch Date: July 18, 2017

    Number of Pages: 193

    Geography Coverage: Global

    Available Format: PDF

    Price For Single User License: USD 2,000

    Price For Site User License: USD 4,000

    Price For Global User License: USD 6,000

    Delivery Time: Within 24 Hours (During Working

    Days)

  • www.MarketResearchReports.com

    About the Report

    Diabetic Macular Edema - Pipeline Review, H2

    2017, provides an overview of the Diabetic Macular

    Edema (Metabolic Disorders) pipeline landscape.

    Diabetic macular edema (DME) occurs when blood

    vessels in the retina of patients with diabetes

    begin to leak into the macula, the part of the eye

    responsible for detailed central vision.

  • www.MarketResearchReports.com

    Report Highlights;

    This report provides comprehensive information on the

    therapeutics under development for Diabetic Macular

    Edema (Metabolic Disorders), complete with analysis by

    stage of development, drug target, mechanism of action

    (MoA), route of administration (RoA) and molecule type.

    The guide covers the descriptive pharmacological

    action of the therapeutics, its complete research and

    development history and latest news and press

    releases.

    The Diabetic Macular Edema (Metabolic Disorders)

    pipeline guide also reviews of key players involved in

    therapeutic development for Diabetic Macular Edema

    and features dormant and discontinued projects.

  • www.MarketResearchReports.com

    Report Highlights; Continues

    The guide covers therapeutics under Development by

    Companies /Universities /Institutes, the molecules

    developed by Companies in Pre-Registration, Phase III,

    Phase II, Phase I, IND/CTA Filed, Preclinical and

    Discovery stages are 1, 4, 18, 6, 1, 21 and 3 respectively.

    Diabetic Macular Edema (Metabolic Disorders) pipeline

    guide helps in identifying and tracking emerging players

    in the market and their portfolios, enhances decision

    making capabilities and helps to create effective

    counter strategies to gain competitive advantage.

    The guide is built using data and information sourced

    from Publishers proprietary databases,

    company/university websites, clinical trial registries,

    conferences, SEC filings, investor presentations and

    featured press releases from company/university sites

    and industry-specific third party sources.

  • www.MarketResearchReports.com

    Scope:

    The pipeline guide provides a snapshot of the global

    therapeutic landscape of Diabetic Macular Edema

    (Metabolic Disorders).

    The pipeline guide reviews pipeline therapeutics for

    Diabetic Macular Edema (Metabolic Disorders) by

    companies and universities/research institutes based

    on information derived from company and industry-

    specific sources.

    The pipeline guide covers pipeline products based on

    several stages of development ranging from pre-

    registration till discovery and undisclosed stages.

    The pipeline guide features descriptive drug profiles

    for the pipeline products which comprise, product

    description, descriptive licensing and collaboration

    details, R&D brief, MoA & other developmental

    activities.

  • www.MarketResearchReports.com

    Scope: Continues

    The pipeline guide reviews key companies involved in

    Diabetic Macular Edema (Metabolic Disorders)

    therapeutics and enlists all their major and minor

    projects.

    The pipeline guide evaluates Diabetic Macular Edema

    (Metabolic Disorders) therapeutics based on

    mechanism of action (MoA), drug target, route of

    administration (RoA) and molecule type.

    The pipeline guide encapsulates all the dormant and

    discontinued pipeline projects.

    The pipeline guide reviews latest news related to

    pipeline therapeutics for Diabetic Macular Edema

    (Metabolic Disorders)

  • www.MarketResearchReports.com

    Reasons to buy:

    Procure strategically important competitor information,

    analysis, and insights to formulate effective R&D

    strategies.

    Recognize emerging players with potentially strong

    product portfolio and create effective counter-strategies

    to gain competitive advantage.

    Find and recognize significant and varied types of

    therapeutics under development for Diabetic Macular

    Edema (Metabolic Disorders).

    Classify potential new clients or partners in the target

    demographic.

    Develop tactical initiatives by understanding the focus

    areas of leading companies.

    Plan mergers and acquisitions meritoriously by

    identifying key players and its most promising pipeline

    therapeutics.

  • www.MarketResearchReports.com

    Reasons to buy: Continues

    Formulate corrective measures for pipeline projects by

    understanding Diabetic Macular Edema (Metabolic

    Disorders) pipeline depth and focus of Indication

    therapeutics.

    Develop and design in-licensing and out-licensing

    strategies by identifying prospective partners with the

    most attractive projects to enhance and expand

    business potential and scope.

    Adjust the therapeutic portfolio by recognizing

    discontinued projects and understand from the know-

    how what drove them from pipeline.

  • www.MarketResearchReports.com

    Report Coverage:

    1. Introduction

    2. Report Coverage

    3. Diabetic Macular Edema - Overview

    4. Diabetic Macular Edema - Therapeutics

    Development

    5. Diabetic Macular Edema - Therapeutics

    Assessment

    6. Diabetic Macular Edema - Therapeutics

    Assessment

    7. Diabetic Macular Edema - Dormant Projects

    8. Appendix

    For more details regarding Report coverage see the last slideAll logos and Images mentioned on this slide belong to their respective owners.

  • www.MarketResearchReports.com

    Company Coverage: (Partial List)

    1. Boehringer Ingelheim GmbH

    2. Cell Medica Ltd

    3. Clearside BioMedical Inc

    4. Coherus Bio Sciences Inc

    5. EyeGate Pharmaceuticals Inc

    6. F. Hoffmann-La Roche Ltd

    7. Formycon AG

    8. Genmab A/S

    9. GlaxoSmithKline Plc

    10. Icon Bioscience Inc

    11. Kala Pharmaceuticals Inc

    12. Kalvista Pharmaceuticals Inc

    13. Lupin Ltd

    For more details regarding Report coverage see the last slideAll logos and Images mentioned on this slide belong to their respective owners.

  • www.MarketResearchReports.com

    Custom Research:

    Are you an industry professional, entrepreneur,

    venture capitalist, investors and organization, then let

    us know your specific research requirements. Our goal

    is to cater to your requirements be it for a custom

    market research project, syndicated research report on

    a specific market or industry sector, newsletter creation,

    case study development or anything else related to

    marketing research.

    For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

    For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

    http://www.marketresearchreports.com/idea-centerhttp://www.marketresearchreports.com/subscribe-to-newsletter

  • www.MarketResearchReports.com

    How To Buy This Report?

    Visit following URL to see Table of Content and

    purchase this publication:

    http://mrr.cm/UqG

    About Market Research Reports, Inc.

    Market Research Reports provides a customized set

    of reports from reputed Publishers, built on the

    intelligence available within organizations and

    leverages on our motto of Intelligence Redefined.

    Contact : Mr. Sudeep Chakravarty

    Email : [email protected]

    Phone: +1-302-703-9904 (USA) +91-8762746600 (India)

    http://mrr.cm/UqGmailto:[email protected]